SCHEMBL17491537

SCHEMBL17491537

O=C(Nc1cc(-c2cnco2)cc(C(F)(F)F)c1)c1cccs1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TRPA1 O75762 8/20 0.60
▸ IMPDH2 P12268 1/20 0.57
▸ MAPT P10636 3/20 0.48
▸ KDM4E B2RXH2 2/20 0.48
▸ POLB P06746 1/20 0.48
▸ RXFP1 Q9HBX9 1/20 0.48
▸ GAA P10253 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ PTBP1 P26599 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ KLF5 Q13887 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ ABL1 P00519 1/20 0.45
▸ MEN1 O00255 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17491420 0.83 NPC1 (0.65) TRPA1IMPDH2MAPTKDM4ERXFP1
SCHEMBL17491404 0.80 MEN1 (0.61) TRPA1KDM4ERXFP1ALDH1A1LMNA
SCHEMBL17491482 0.80 CES1 (0.47) KDM4EALDH1A1LMNASMN1; SMN2NPC1
SCHEMBL17491499 0.79 P2RX1 (0.53) MAPTKDM4ERXFP1MAPK1ALDH1A1
SCHEMBL17491467 0.79 KDM4E (0.66) TRPA1IMPDH2KDM4ERXFP1ALDH1A1
SCHEMBL17491415 0.79 BRAF (0.47) IMPDH2MAPTKDM4EMAPK1ALDH1A1
SCHEMBL17491475 0.78 P2RX1 (0.51) MAPTKDM4ERXFP1ALDH1A1LMNA
SCHEMBL17491408 0.77 EGFR (0.43) IMPDH2KDM4EMAPK1ALDH1A1LMNA
SCHEMBL17491447 0.76 IMPDH2 (0.51) IMPDH2MAPTKDM4ERXFP1GAA
SCHEMBL17491488 0.76 EGFR (0.42) IMPDH2KDM4EMAPK1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982670-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2018-11-07 — — EP disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-9624184-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-04-18 — — US disclosed
US-20160052897-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-02-25 — — US disclosed
EP-2982670-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160052897-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 TRPA1 611/4885IMPDH2 1603/4885MAPT 78/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback